Beximco Pharma
Beximco Pharmaceuticals Ltd also known as Beximco Pharma, is a pharmaceutical company in Bangladesh. It is part of the Beximco Group of Companies. Corporate history. Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of United States. Today Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets. It was the first drug company from Bangladesh to sell its products in the US. In May 2020, the company  introduced the world's first generic remdesivir for COVID-19 treatment. Beximco Pharma became the first company to obtain production and marketing authorization for Molnupiravir, the first and only specific oral anti covid drug in Bangladesh along with Eskayef Pharmaceuticals. Beximco Pharma's branded generic version of molnupiravir is being marketed as Emorivir. Factories. Beximco Pharma manufacturing facilities are spread across a site located in Dhaka, Bangladesh. The facilities consist of a number of purpose-built plants, including a new Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research laboratory and a number of warehouses . The plant and machinery of the facilities were designed, produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United Kingdom, amongst others. Exports. On August, 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-member Association of South East Asian Nations (ASEAN) to import Beximco's drugs. Beximco Managing Director Nazmul Hassan said that exports to the Philippines include metered dose inhalers, and nasal sprays, and other medications. The Philippine pharmaceutical market ($1.3 billion in 2007), is highly dependent on imported medicines.